The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Inc have entered into a new collaboration focused on regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders with the goal of developing new treatments.

The SMA Foundation–PTC partnership will provide funding, managed by the SMA Foundation, to academic institutions and other collaborators to advance foundational research in the area of regenerative medicine.

“In neuromuscular disease, correcting the underlying cause is just the first step. Patients need therapies to help restore lost function. We are excited to expand our partnership with PTC Therapeutics to empower researchers to address this therapeutic gap in neuromuscular disorders with an emphasis on SMA.

“Our longstanding partnership with PTC lets us harness our research capabilities and PTC’s drug discovery and development expertise and access to core technology platforms, all of which supported the recent approval of Evrysdi (risdiplam) in SMA. We look forward to our initial funding of new projects under the collaboration with PTC.”

— Loren Eng, President, The SMA Foundation

“We have had an extremely productive partnership with the SMA Foundation for well over a decade and are excited to continue this collaboration to investigate regenerative medicine to find new therapies for patients with SMA and other neuromuscular disorders. The SMA Foundation has been the leader in supporting SMA research, and we look forward to doing the critical work to accelerate the next generation of therapeutics for these patients.”

— Stuart W. Peltz, PhD, Chief Executive Officer of PTC Therapeutics

[Source(s): PTC Therapeutics Inc, PR Newswire]

Related Content:
A Closer Look at Gene Therapy for Spinal Muscular Atrophy in Kids
Not Just a Kids’ Disease – Care of Adults with Spinal Muscular Atrophy is Focus of Study
Children with Spinal Muscular Atrophy Use Exoskeleton to Walk